SAGE analysis demonstrates increased expression of TOSO contributing To fas-mediated resistance in CLL

Blood

Volumn 112, Issue 2, 2008, Pages 394-397

  Proto Siqueira, Rodrigo ^a,b   Panepucci, Rodrigo A ^a   Careta, Francisco P ^a   Lee, Abigail ^b   Clear, Andrew ^b   Morris, Kelly ^b   Owen, Carolyn ^b   Rizzatti, Edgar G ^a   Silva Jr , Wilson A ^a   Falcão, Roberto P ^a   Zago, Marco A ^a   Gribben, John G ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; FAS ANTIGEN; PROTEIN BCL 2; REGULATOR OF FAS INDUCED APOPTOSIS PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; MEMBRANE PROTEIN; TOSO PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GENE LIBRARY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SERIAL ANALYSIS OF GENE EXPRESSION; TOSO GENE; B CELL LEUKEMIA; GENE EXPRESSION PROFILING; GENETICS; METHODOLOGY; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, CD95; APOPTOSIS REGULATORY PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE PROTEINS;

EID: 47649116872     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-124065     Document Type: Article

References (26)

1. Obennann EC, Went P, Tzankov A, et al. Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase. J Clin Pathol. 2007;60: 794-797.
2. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
3. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105-111.
4. Rassenti LZ, Huynh L, Toy TL et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
5. Oppezzo P, Vasconcelos Y. Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood. 2005;106:650-657.
6. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
7. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194:1639-1647.
8. Greaney P, Nahimana A. Lagopoulos L. et al. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk Res. 2006; 30:415-426.
9. Romano C, De Fanis U, Sellitto A, et al. Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis. Immunol Lett. 2005; 97:131-139.
10. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524-15529.
11. Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol. 2004;22:3937-3949.
12. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood. Prepublished on January 23, 2008, as doi 10.1182/blood-2007-06-093906.
13. Silva WAJr, Covas DT, Panepucci RA, et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells. 2003;21:661-669.
14. Hashimoto S, Nagai S, Sese J, et al. Gene expression profile in human leukocytes. Blood. 2003;101:3509-3513.
15. National Center for Biotechnology Information. CGAP: The Cancer Genome Anatomic Project. http://cgap. nic.nih.gov/SAGE. Accessed October 20, 2007.
16. Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. 2006;24:5052-5059.
17. Center for Cell-Based Therapy. GDM: Genome Data Mining, http://gdm.fmrp.usp. br/downloads/SAGE/data/. Accessed May 12, 2008.
18. Gricks CS, Zahrieh D, Zauls AJ, et al. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood. 2004;104:4002-4009.
19. Vasconcelos Y De Vos J, Vallat L, et al. Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. Leukemia. 2005;19:2002-2005.
20. Hitoshi Y, Lorens J, Kitada SI, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity. 1998;8:461-471.
21. Achiron A, Feldman A, Mandel M, Gurevich M. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann N Y Acad Sci. 2007; 1107:155-167.
22. Song Y, Jacob CO. The mouse cell surface protein TOSO regulates Fas/Fas ligand-induced apoptosis through its binding to Fas-associated death domain. J Biol Chem. 2005;280:9618-9626.
23. deTotero D, Montera M, Rosso O, et al. Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. Hematol J. 2004;5:152-160.
24. Agrawal SG, Liu FT, Wiseman C, et al. Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood. 2008;111:2790-2796.
25. Liu FT, Agrawal SG, Gribben JG, et al. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood. 2008; 111:2797-2805.
26. + lymphoma cell lines. Blood. 2008;111:1594-1602.